LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Kodu・Aktsiate loetelu・Puma Biotechnology Inc

Puma Biotechnology Inc

Avatud

SektorTervishoid

7.2 -1.23

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.19

Max

7.35

Põhinäitajad
By Trading Economics
Sissetulek	-16M -3.8M
Müük	-31M 45M
P/E Sektori keskmine	14.75 50.102
Aktsiakasum	-0.04
Kasumimarginaal	-8.375
Töötajad	179
EBITDA	-28M -1.3M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-31.22% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-23M 360M
Eelmine avamishind	8.43
Eelmine sulgemishind	7.2

Uudiste sentiment

By Acuity

50%

138 / 344 Pingereas Healthcare

Puma Biotechnology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. mai 2026, 21:33 UTC

Tulu

Correction to Salesforce 1Q Sales, Profit Rise Article

27. mai 2026, 21:00 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. mai 2026, 20:18 UTC

Tulu

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. mai 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. mai 2026, 21:08 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. mai 2026, 21:02 UTC

Tulu

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. mai 2026, 20:59 UTC

Omandamised, ülevõtmised, äriostud

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. mai 2026, 20:55 UTC

Tulu

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. mai 2026, 20:48 UTC

Tulu

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. mai 2026, 20:45 UTC

Tulu

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. mai 2026, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Webster Financial Stockholders Approve Sale to Banco Santander

27. mai 2026, 20:32 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. mai 2026, 20:32 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. mai 2026, 20:30 UTC

Tulu

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. mai 2026, 20:30 UTC

Omandamised, ülevõtmised, äriostud

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. mai 2026, 20:22 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:16 UTC

Tulu

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. mai 2026, 20:13 UTC

Tulu

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. mai 2026, 20:13 UTC

Tulu

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. mai 2026, 20:12 UTC

Tulu

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Võrdlus sarnastega

Hinnamuutus

Puma Biotechnology Inc Prognoos

Hinnasiht

By TipRanks

-31.22% langus

12 kuu keskmine prognoos

Keskmine 5 USD -31.22%

Kõrge 5 USD

Madal 5 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Puma Biotechnology Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Puma Biotechnology Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

138 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.